You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
21 April 2026 - Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) on Tuesday announced the publication of a landmark real-world study of its RefluxStop device in Scientific Reports, part of the Nature port...
21 April 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab in patients with PD-1/PD-L1 refractory advanced me...
21 April 2026 - Rznomics Inc, a clinical-stage biopharmaceutical company based in South Korea, announced on Monday the presentation of interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in...
21 April 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Monday that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemoth...
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belantamab mafodotin) in combination with bortezomib and...
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically significant lower systemic reactogenicity compared to...
20 April 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-33-targeting biologic, tozorakimab, achieved a stat...